Peyronie's disease is an inflammatory disorder, which causes thickening of the tunica albuginea of the penis. Peyronie's disease has a variable natural history and the assessment and management of the disease has yet to be standardised. The case notes of 97 patients with a diagnosis of Peyronie's disease were retrospectively reviewed at a single tertiary referral centre. Patients who were able to achieve sexual penetrative activity to the satisfaction of both partners were managed conservatively. Patients who were unable to achieve penetrative sexual activity were given intra-cavernosal prostaglandin, with those achieving a satisfactory erection being offered appropriate surgical intervention. The mean age at presentation was 50 years (range 18-82). A total of 59 (61%) men were able to have penetrative sex at the time of presentation. Following initial conservative management, only five (8%) of this group had disease progression, which stopped them from being able to penetrate. In all 38 (39%) men who were not able to penetrate at presentation were offered surgical intervention. In all 24 (63%) of these men chose to have surgical intervention. Tunical plication resulted in the ability to penetrate in 77% of men choosing this option whereas only 46% of men undergoing autologous saphenous vein grafting were able to have penetrative sex. Assessment of penetrative sexual function is an essential component of the management of patients with Peyronie's disease. This enables appropriate counselling with respect to possible conservative management or the most appropriate surgical intervention. The majority of patients with Peyronie's disease can achieve sexual penetrative activity, many without surgical intervention.
Introduction
Peyronie's disease is an inflammatory condition of unknown aetiology, which causes thickening of the tunica albuginea of the penis and may lead to penile swelling, induration, shortening and curvature in addition to painful erections and dyspareunia for both partners. Peyronie's disease has a prevalence in the region of 3.2-8.9% [1] [2] [3] [4] and when present is associated with erectile dysfunction in over 40% of men. 1 Assessing treatments in Peyronie's disease is difficult due to the unpredictable natural course of the disease, which can range from spontaneous disease regression in rare cases to progression with severe penile deformity. [5] [6] [7] Furthermore, there remains a lack of standardisation with respect to the evaluation of men with Peyronie's disease and a variety of outcome measures, both subjective and objective, have been used to measure the success of the various treatment modalities available. 5, 8 In this study, we aim to identify an assessment and management algorithm using the ability to successfully perform penetrative sexual activity at presentation as a treatment arbiter.
Patients and methods
A retrospective review of case notes was performed at a single tertiary referral centre from January 2001 to May 2009. Patients were selected using an International Classification of Disease version 10 (ICD 10), code N48.9 (disorder of the penisunspecified), revealing 600 potential cases. Case notes were reviewed by the authors and 97 patients were included with a definitive documented diagnosis of Peyronie's disease. Peyronie's disease was indicated by a detailed medical and sexual history, a palpable plaque on physical examination, with or without a visible curvature following an intracavernosal injection of prostaglandin.
At clinical review and examination, all patients with a diagnosis of Peyronie's disease were counselled regarding the pathology and evidence-based outcomes from medical and surgical management. Patients were directly questioned regarding their ability to perform penetrative sexual activity to the mutual satisfaction of both partners. Penetrative sexual activity was adopted as the primary outcome measure for conservative and surgical treatments in Peyronie's disease.
Patients who were able to have penetrative sexual activity at presentation were treated conservatively with advice on the natural history of Peyronie's disease and where required, for erectile dysfunction, PDE-5 inhibitor pharmacotherapy. Where possible these patients were discharged at first presentation and advised to re-present should their ability to achieve penetrative sexual activity diminish or disappear in the event.
Patients who at the presentation reported an inability to perform satisfactory penetrative sexual activity were assessed with an intra-cavernosal injection of prostaglandin. This allowed an accurate assessment of erectile quality in terms of rigidity and curvature and helped guide counselling regarding operative intervention. Patients were counselled regarding tunical shortening procedures if they had less than 601 angulation. Patients who had more than 601 of angulation, hinge defect, hourglass deformity or other complex deformity were offered a tunical lengthening procedure. Patients who had no erectile response to prostaglandin were offered penile prosthetic implantation.
Surgical intervention was broadly classified as either tunical shortening, tunical defect lengthening or penile prosthesis surgery. Tunical shortening operations included Nesbit's operation, modified Nesbit's operation and any other tunical plication procedures. Tunical lengthening operations included incision and excision of the Peyronie's plaque with autologous saphenous vein grafting. All penile prostheses inserted were three-piece inflatable implants (Coloplast Titan).
Results
Our series revealed 97 men with Peyronie's disease with a mean age of 50 years (range 18-82). A total of 59 (61%) men claimed to be achieving satisfactory penetrative sexual intercourse at the time of presentation whereas the remaining 38 (39%) were either having difficulty or were unable to achieve penetration. As expected the range of presenting symptoms varied considerably with the most frequent being penile deformity (63%), penile lump (19%), pain on erection (8%), penile shortening (6%) and erectile dysfunction (4%). At first presentation, 76% of patients had symptoms for 12 months or more, and 55% had symptoms for 18 months or more. In addition, 22 (22%) men were experiencing active penile pain suggesting an early stage in the natural history of their condition. None of the patients had received previous treatment for their Peyronie's disease.
A total of 96 (99%) patients were classed as having idiopathic acquired Peyronies disease and one (1%) patient had acquired Peyronie's disease secondary to penile trauma. The mean duration of symptoms before presentation was 21 months, with a range from 1 month to 192 months. Comorbidities in patients with Peyronie's disease included 11 (11%) patients with known diabetes, six (6%) patients with ischaemic heart disease, four (4%) patients with hypercholesterolaemia and one (1%) patient with peripheral vascular disease.
Peyronie's patients performing penetrative sexual activity at presentation Of the 59 men able to achieve penetrative sexual activity at presentation, 80% were successfully managed with advice on Peyronie's disease, its natural history and likely sequelae (Figure 1 ). Such patients were offered PDE-5 inhibitor pharmacotherapy, if required to enhance sexual function, an offer taken up successfully by 13% of this cohort. Within this group, the mean time of symptom onset to presentation was 19.5 months (range .
Five (8%) patients who were initially penetrating at presentation had disease progression and they were no longer able to achieve sexual penetration. Within this group of patients, four had tunical shortening operations, which allowed penetrative sexual activity in three patients (75%). One patient had a tunical lengthening procedure but was unable to penetrate before or following surgery. None of this group of patients were experiencing penile pain at presentation and the mean time from onset of symptoms to surgery was 66 months (range ).
Peyronie's disease patients not able to perform penetrative sexual activity at presentation Of the 38 patients unable to achieve satisfactory penetrative intercourse at the time of presentation, 24 (63%) underwent surgical correction of their Peyronie's disease (Figure 2 ). Within this group, the mean time of symptom onset to presentation was 26 months (range 5-72) and the mean time from symptom onset to surgical intervention was 31
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Tunical shortening procedures were performed on nine patients and resulted in successful penetrative sexual activity in seven (78%) patients. In all 13 patients had tunical lengthening procedure enabling successful penetration in six (46%).
At the time of evaluation, two (8.3%) patients were not able to achieve an erection with intracavernosal prostaglandin pharmacotherapy and chose to undergo penile prosthesis implantation. One patient was able to achieve successful penetrative sexual activity with the aid of a prosthesis. The other patient had a functional penile prosthesis but was unable to penetrate due to a small penis.
In all 14 (37%) patients opted for conservative or medical management despite being unable to achieve penetrative sexual activity. Nine (25%) patients were offered surgical intervention but chose not to have surgery or failed to attend further followup. Three patients were listed for surgical procedures but decided against proceeding with surgery and two patients were successfully treated with PDE-5 inhibitors and were able to penetrate. Progression of disease requiring surgical treatment 5 (8%) Figure 1 Peyronie's disease patients who were able to perform penetrative sexual activity at presentation. Figure 2 Peyronie's disease patients who were not able to perform sexual penetrative activity at presentation.
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Discussion
Gelbard et al. 9 showed that in a group of patients affected by Peyronie's disease, over a period of 3-8 months, 13% of patients had spontaneous resolution of Peyronie's plaques with time and 47% of patients had little or no change in the disease. Mulhall et al. 6 showed that in men with Peyronie's disease who had curvature, 12% showed an improvement and 40% remained stable over a mean follow-up of 14.5 months, with the mean time from symptom onset to presentation of 3.5 months (range 2-5).
Our series demonstrates that the majority of men (92%) with Peyronie's disease who are achieving satisfactory penetrative sexual intercourse at presentation continue to do so following counseling and reassuring advice regarding their condition and its likely natural history. Where patients progressed to needing surgical correction to allow penetration, two (40%) patients were not able to perform sexual penetrative activity following surgery.
There is a lack of evidence for the role of medical management in Peyronie's disease. 5 Medical agents such as potassium para-amino benozoate (Potaba) may prevent disease progression 5, 10 and penile pain related to the disease, however, they do not reduce plaque size and do not result in significant disease regression. Other medical agents such as vitamin E, tamoxifen and colchicine have not shown any longterm benefit to patients in placebo-controlled randomized controlled trials. [11] [12] [13] Intra-lesional agents such as verapamil, steroids and interferons have not been adopted into clinical practice due to limited evidence for their effectiveness. 5, 14, 15 When patients were not able to penetrate at presentation and had stable disease for 12 months or more, surgical management was offered. Most men chose to have either a tunical shortening or lengthening procedure with a varying ability to achieve sexual penetrate activity following surgery. In general, men undergoing tunical shortening achieved an excellent outcome with 78% being able to achieve satisfactory penetrative sexual activity postoperatively. This figure compares favourably with other published series with rates ranging from 62 to 94%. [16] [17] [18] Patients undergoing tunical lengthening procedures had a less favourable outcome with only 46% being able to achieve satisfactory penetrative function. A recent study by Kadioglu et al. 19 reported such success in over 75% of patients undergoing autologous saphenous vein interposition grafting. In a review of published studies, tunical lengthening and autologous saphenous vein grafting had postoperative erectile dysfunction ranging from 0 to 46%. 20 At presentation, 39% of men in our series were either having difficulty achieving sexual penetration or were unable to perform satisfactory penetrative sexual activity. Our results are similar to a large cross-sectional survey 1 wherein 41% of men with a palpable plaque could not achieve penetrative sexual activity. In another study, Weidner et al. 21 showed that 31.5% of men with Peyronie's disease were unable to perform penetrative sexual intercourse. The underlying causes of inability to perform intercourse included complete loss of erection in 25% of the entire series. The most common causes of loss of erections included veno-occlusive dysfunction, abnormal arterial blood flow and plaque associated abnormal venous drainage.
In our series only two men underwent implantation of a penile prosthesis. Management and patient selection for penile prosthesis operations was similar in other series, where patients were offered penile prostheses as first line management of Peyronies disease with concomitant erectile dysfunction resistant to therapy. 6, 19, 22 There are numerous studies comparing the efficacies of various surgical techniques for the treatment of Peyronie's disease. Postoperative outcomes vary greatly with factors such as surgical competency and the quality of pre and postoperative care being largely responsible for such large discrepancies in result. It is inevitable perhaps, that in a disease with a variable natural history a major factor in successful outcomes is likely to be patient selection for surgical intervention. Unfortunately, the selection methods for patients undergoing conservative or surgical treatments tend to be less well defined than the postoperative outcome parameters.
Proposed recommendations for further assessment and management of Peyronie's disease in a prospective study 1. We propose that all patients who are diagnosed with Peyronie's disease should be assessed with a questionnaire for sexual function such as the 5-item abridged version of the International Index for Erectile Function-5 23 or the Sexual Encounter Profile diary Questions 2 (SEP2: successful penetration) and 3 (SEP3: successful completion of intercourse) ( Figure 3 ). All patients with erectile dysfunction should be offered PDE-5 inhibitor pharmacotherapy. 24, 25 As there have been no studies into this therapy in relation to Peyronie's disease, 26 this area needs further assessment with double-blind placebo-controlled randomized controlled trials. 2. Patients who have had stable disease for at least 12 months, 6, 20 and are unable to achieve penetrative sexual activity with PDE-5 inhibitors, should be assessed with intra-cavernosal prostaglandin injections to determine their erectile potential for the future. activity should be offered a tunical shortening procedure if they have less than 601 angulation. 20, 22 Patients with more than 601 of angulation, hinge defect, hourglass deformity or other complex deformity should be offered a tunical lengthening procedure or penile prosthesis if they have suboptimal erectile capacity. 20, 22 Such patients, however, must be thoroughly counseled regarding the much higher risk of postoperative erectile dysfunction as a consequence of such a procedure. Patients who do not respond to intracavernosal prostaglandin with an erection suitable for penetrative sexual activity should be offered a penile prosthesis. 22 
Conclusions
The majority of patients with Peyronie's disease who are able to achieve satisfactory penetrative sexual intercourse can be managed with conservative management with a high expectation of being able to continue to perform penetrative sexual activity. Patients who are unable to penetrate at presentation and do not respond to PDE-5 inhibitor pharmacotherapy, should be assessed carefully, before counselling in regard to the available surgical treatment options. Figure 3 Proposed assessment and management algorithm for patients presenting with Peyronie's disease.
